David is a partner in the Corporate and M&A Group, specialising in public and private M&A, equity capital markets transactions, corporate governance and securities law.

David advises international and domestic companies on all aspects of corporate law and governance. He has advised on some of the most high-profile corporate transactions in recent years, including public takeovers, private M&A, private equity and private capital transactions, rights issues, placings and other public offerings, holding company structures, schemes of arrangement and joint ventures. David also advises on corporate governance and securities law issues for listed companies.

David has particular experience in public takeovers, having advised on a number of high-profile recommended and contested/hostile takeovers in recent years, and equity capital markets, where he advises both issuers and banks.

Relevant Experience

  • Advised Avadel Pharmaceuticals plc on its $2.37 bn public takeover by Alkermes plc, including the response to a competing proposal by Lundbeck A/S
  • Advised Mural Oncology plc on its public takeover by XOMA Royalty Inc.
  • Advised Flutter Entertainment plc on its listing on the NYSE and its ongoing international M&A programme, including its merger with The Stars Group Inc valued at £10 billion, its acquisition of Snaitech S.p.A. for $2.3 billion, its acquisition of the minority interest in FanDuel Group Parent LLC for $4.175 billion and its joint venture with NSX Group for $350 million
  • Advised Starwood Capital Group on its strategic equity and debt investment in Echelon Data Centres at a valuation of €2.5 billion
  • Advised Bank of Ireland Group plc on its €11 billion holding company scheme of arrangement
  • Advised Bank of Cyprus Holdings plc on its de-listing from the London Stock Exchange and listing on ATHEX
  • Advised the shareholders of Linesight on the sale of Linesight, the leading construction consultancy group, to IPS – Integrated Project Services LLC
  • Advised Viatris Inc. on the $3.335 billion combination of its biosimilar’s portfolio with Biocon Biologics LimitedBullet point 5
  • Advised Green REIT plc on its €1.34 billion public takeover by Henderson Park
  • Advised ARYZTA AG on its CHF 908 million rescue rights issue and successful defence of an activist shareholder contest